Opus Genetics vs uniQure
IRD and QURE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IRD and QURE compare
uniQure is the larger company, worth 4.8 times as much as Opus Genetics ($1.7B against $359M).
uniQure grew revenue faster over the last twelve months (28.0% versus −45.9% for Opus Genetics).
uniQure keeps more of each dollar of sales as profit, with a net margin of −1155% compared with −1727% at Opus Genetics.
Opus Genetics scores higher on the StockData Score (5 against 4 for uniQure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IRD | QURE |
|---|---|---|
| Size and price | ||
| Market cap | $359M | $1.7B |
| Share price | $4.31 | $24.59 |
| Change, 1 year | 119% | −6.0% |
| Change, 5 years | 18.4% | −17.1% |
| Beta (5Y) | 0.98 | 1.68 |
| Employees | 27 | 221 |
| StockData Score | ||
| Total score | 5 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 4 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 45.3× (better) | 84.6× |
| P/B | 9.3× | 5.8× (better) |
| FCF yield | – | −11.3% |
| Fair value | $0.739 | $6.19 |
| Margin of safety | −483% | −297% (better) |
| Growth | ||
| Revenue growth (TTM) | −45.9% | 28.0% (better) |
| Revenue growth, 5Y average | – | −15.6% |
| Profitability | ||
| Gross margin | – | 93.9% |
| Operating margin | −778% (better) | −1002% |
| Net margin | −1727% | −1155% (better) |
| FCF margin | – | −957% |
| Return on equity | −616% | −89.0% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.17 (better) |
| Interest coverage | −217.5× | −3.5× (better) |
| Current ratio | 9.65 | 11.52 (better) |
| Altman Z-score | −1.73 | −0.57 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | −0.68% | – |
| Shareholder yield | −0.68% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 72.8% | 96.0% |
| Held by insiders | 37.6% | 2.1% |
| Insider net buying, 12 months | −$19.4M (better) | −$20.2M |
| Short interest, % of float | 20.9% | 12.5% |
Go deeper
- IRD stock overview
- IRD income statement
- IRD valuation and score
- QURE stock overview
- QURE income statement
- QURE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.